Johanna Hynninen - Search Results

Year	Number of Results
2011	1
2012	2
2013	2
2014	1
2015	2
2016	4
2017	3
2018	4
2019	8
2020	9
2021	10
2022	5
2023	9
2024	8

1

Is it safe to operate selected low-risk endometrial cancer patients in secondary hospitals?

Narva S, Polo-Kantola P, Oksa S, Kallio J, Huvila J, Rissanen T, Hynninen J, Hietanen S, Joutsiniemi T. Narva S, et al. Among authors: hynninen j. Eur J Surg Oncol. 2024 Apr 1;50(6):108317. doi: 10.1016/j.ejso.2024.108317. Online ahead of print. Eur J Surg Oncol. 2024. PMID: 38581756

2

Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer.

Launonen IM, Erkan EP, Niemiec I, Junquera A, Hincapié-Otero M, Afenteva D, Liang Z, Salko M, Szabo A, Perez-Villatoro F, Falco MM, Li Y, Micoli G, Nagaraj A, Haltia UM, Kahelin E, Oikkonen J, Hynninen J, Virtanen A, Nirmal AJ, Vallius T, Hautaniemi S, Sorger P, Vähärautio A, Färkkilä A. Launonen IM, et al. Among authors: hynninen j. bioRxiv [Preprint]. 2024 Mar 20:2024.03.19.585657. doi: 10.1101/2024.03.19.585657. bioRxiv. 2024. PMID: 38562799 Free PMC article. Preprint.

3

PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.

Rausio H, Cervera A, Heuser VD, West G, Oikkonen J, Pianfetti E, Lovino M, Ficarra E, Taimen P, Hynninen J, Lehtonen R, Hautaniemi S, Carpén O, Huhtinen K. Rausio H, et al. Among authors: hynninen j. Neoplasia. 2024 May;51:100987. doi: 10.1016/j.neo.2024.100987. Epub 2024 Mar 14. Neoplasia. 2024. PMID: 38489912 Free PMC article.

4

Locus-specific LINE-1 expression in clinical ovarian cancer specimens at the single-cell level.

Perkiö A, Pradhan B, Genc F, Pirttikoski A, Pikkusaari S, Erkan EP, Falco MM, Huhtinen K, Narva S, Hynninen J, Kauppi L, Vähärautio A. Perkiö A, et al. Among authors: hynninen j. Sci Rep. 2024 Feb 21;14(1):4322. doi: 10.1038/s41598-024-54113-w. Sci Rep. 2024. PMID: 38383551 Free PMC article.

5

Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma.

Jamalzadeh S, Dai J, Lavikka K, Li Y, Jiang J, Huhtinen K, Virtanen A, Oikkonen J, Hietanen S, Hynninen J, Vähärautio A, Häkkinen A, Hautaniemi S. Jamalzadeh S, et al. Among authors: hynninen j. BMC Cancer. 2024 Feb 5;24(1):173. doi: 10.1186/s12885-024-11895-6. BMC Cancer. 2024. PMID: 38317080 Free PMC article.

6

HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.

Koskela H, Li Y, Joutsiniemi T, Muranen T, Isoviita VM, Huhtinen K, Micoli G, Lavikka K, Marchi G, Hietanen S, Virtanen A, Hautaniemi S, Oikkonen J, Hynninen J. Koskela H, et al. Among authors: hynninen j. Gynecol Oncol. 2024 Jan;180:91-98. doi: 10.1016/j.ygyno.2023.11.027. Epub 2023 Dec 6. Gynecol Oncol. 2024. PMID: 38061276 Free article. Clinical Trial.

7

Quantification of cell death and proliferation of patient-derived ovarian cancer organoids through 3D imaging and image analysis.

Skorda A, Lauridsen AR, Huhtinen K, Lahtinen A, Senkowski W, Oikkonen J, Hynninen J, Hautaniemi S, Kallunki T. Skorda A, et al. Among authors: hynninen j. STAR Protoc. 2023 Dec 15;4(4):102683. doi: 10.1016/j.xpro.2023.102683. Epub 2023 Nov 16. STAR Protoc. 2023. PMID: 37976153 Free PMC article.

8

Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence.

Marchi G, Rajavuori A, Nguyen MTN, Huhtinen K, Oksa S, Hietanen S, Hautaniemi S, Hynninen J, Oikkonen J. Marchi G, et al. Among authors: hynninen j. Transl Oncol. 2024 Jan;39:101814. doi: 10.1016/j.tranon.2023.101814. Epub 2023 Nov 2. Transl Oncol. 2024. PMID: 37924564 Free PMC article.

9

Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments.

Rannikko JH, Bono P, Hynninen J, Hollmén M. Rannikko JH, et al. Among authors: hynninen j. Cancer Immunol Res. 2024 Jan 3;12(1):48-59. doi: 10.1158/2326-6066.CIR-23-0350. Cancer Immunol Res. 2024. PMID: 37922365 Free PMC article.

10

H&E image analysis pipeline for quantifying morphological features.

Ariotta V, Lehtonen O, Salloum S, Micoli G, Lavikka K, Rantanen V, Hynninen J, Virtanen A, Hautaniemi S. Ariotta V, et al. Among authors: hynninen j. J Pathol Inform. 2023 Oct 5;14:100339. doi: 10.1016/j.jpi.2023.100339. eCollection 2023. J Pathol Inform. 2023. PMID: 37915837 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

60 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year